Skip to main content

MyMD Pharmaceuticals, Inc. (MYMD)

NASDAQ: MYMD · IEX Real-Time Price · USD
8.93 0.18 (2.06%)
Oct 25, 2021 4:00 PM EDT - Market closed
Market Cap330.37M
Revenue (ttm)n/a
Net Income (ttm)-29.99M
Shares Out35.91M
EPS (ttm)-0.75
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume112,082
Open8.77
Previous Close8.75
Day's Range8.65 - 9.09
52-Week Range3.30 - 10.48
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 15, 2021

About MYMD

MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, engages in the development of drug candidates to treat autoimmune, and aging and age-related diseases. It is developing MYMD-1, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel diseases, as well as to treat age-related illnesses such as, frailty and sarcopenia. The company is also developing Supera-CBD, a synthetic preclinical c...

IndustryBiotechnology
Founded2014
CEOHoward Yeaton
Employees6
Stock ExchangeNASDAQ
Ticker SymbolMYMD
Full Company Profile

Financial Performance

Financial Statements

News

MyMD Pharmaceuticals to Discuss its Novel Therapies for Aging and Related Diseases at the Dawson James Securities 6th...

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that it ...

6 days ago - Business Wire

MyMD Pharmaceuticals Announces New Data Demonstrating 8,000 Times Higher Potency of Novel Synthetic Supera-CBD over P...

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced new data...

1 month ago - Business Wire

MyMD Pharmaceuticals Announces Fourth Quarter 2021 Initiation of Phase 2 Clinical Trial of MYMD-1 for Extending Healt...

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it ...

1 month ago - Business Wire

MyMD Pharmaceuticals to Present its Novel Therapeutic Platforms for Extending Healthy Lifespan at the H.C. Wainwright...

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, will present at the H.C....

1 month ago - Business Wire

MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Use of Lead Candidate MYMD-1 for Treating Fibrosis and Asthma

BALTIMORE--(BUSINESS WIRE)---- $MYMD--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on ...

2 months ago - Business Wire

MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflamma...

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing...

2 months ago - Business Wire

MyMD Pharmaceuticals Subsidiary Oravax Medical Preparing to Commence Clinical Trials for Oral COVID-19 Vaccine

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing...

Other symbols:ORMP
2 months ago - Business Wire

MyMD Pharma Stock Is Trading Higher As COVID-19 Candidate Effective In Suppressing Cytokine Storm

MyMD Pharmaceuticals Inc (NASDAQ: MYMD) announces that a human cell research study of its lead compound MYMD-1 found the drug to effectively suppress the cytokine storm, a major cause of severity and de...

2 months ago - Benzinga

MyMD Pharmaceuticals' Lead Compound MYMD-1 Shown to Suppress a Major Cause of Death in COVID-19 in Human Cell Study

BALTIMORE, Md.--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on devel...

2 months ago - Business Wire

MyMD Pharmaceuticals' Lead Compound MYMD-1 Shows Commonality in Comparative Study with FDA-Approved Anti-Inflammatory...

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing...

2 months ago - Business Wire

MyMD Pharmaceuticals Announces New Data from Comparative Study on Lead Compound MYMD-1

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (“MyMD”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, toda...

3 months ago - Business Wire

MyMD Pharmaceuticals Set to Join Russell Microcap® Index

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms...

4 months ago - Business Wire

MyMD Pharmaceuticals Appoints David Rini, Professor at the Johns Hopkins School of Medicine, to Scientific Advisory B...

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms...

5 months ago - Business Wire

MyMD Pharmaceuticals Schedules Business Update Conference Call

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms...

5 months ago - Business Wire

Johns Hopkins Medicine Researchers to Present Data on MyMD Pharmaceuticals' Supera-CBD at the 3rd Annual Neuroimmunol...

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms...

5 months ago - Business Wire

MyMD Pharmaceuticals Announces Issuance of Allowance from United States Patent and Trademark Office for Synthetic Can...

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms...

6 months ago - Business Wire

MyMD Pharmaceuticals IPO: 10 Things for MYMD Stock Investors to Know as Shares Surge

MyMD Pharmaceuticals (MYMD) stock is among the biggest movers today with shares soaring just one day after the company's IPO. The post MyMD Pharmaceuticals IPO: 10 Things for MYMD Stock Investors to Kno...

6 months ago - InvestorPlace

Akers Biosciences and MyMD Pharmaceuticals Announce Stockholder Approval of Merger

BALTIMORE--(BUSINESS WIRE)--Akers Biosciences and MyMD Pharmaceuticals Announce Stockholder Approval of Merger

6 months ago - Business Wire

Akers' Proposed Merger Partner MyMD Pharmaceuticals Announces Plans to Initiate COVID-19 Inflammatory Depression Trial

BALTIMORE--(BUSINESS WIRE)--Akers Biosciences, Inc. (NASDAQ: AKER), today announced that its proposed merger partner MyMD Pharmaceuticals, Inc. (“MyMD”), a clinical stage pharmaceutical company committe...

6 months ago - Business Wire

Akers' Proposed Merger Partner MyMD Pharmaceuticals Announces Formation of Scientific Advisory Board

BALTIMORE--(BUSINESS WIRE)--Akers Biosciences, Inc. (Nasdaq: AKER), today announced that its proposed merger partner MyMD Pharmaceuticals, Inc. (“MyMD”), a clinical stage pharmaceutical company committe...

6 months ago - Business Wire

Akers Biosciences Announces Shareholder Meeting to Vote on Business Combination with MyMD Pharmaceuticals

BALTIMORE & THOROFARE, N.J.--(BUSINESS WIRE)--Akers Biosciences, Inc (Nasdaq: AKER), today announced that it has scheduled its general meeting of shareholders (the "Meeting”) to vote on the proposed bus...

7 months ago - Business Wire

SHAREHOLDER ALERT: WeissLaw LLP Reminds NTWN, TLRY, CBLI, and AKER Shareholders About Its Ongoing Investigations

NEW YORK, March 12, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights o...

Other symbols:TLRY
7 months ago - PRNewsWire

Akers Biosciences' Proposed Partner MyMD's Lead Candidate Inhibits Fibrotic Diseases-Associated Biomarkers

Akers Biosciences Inc (NASDAQ: AKER) and its proposed merger partner MyMD Pharmaceuticals Inc have announced new data for MYMD-1 from the Eurofins Discovery Phenotypic Center of Excellence study. MYMD-1...

8 months ago - Benzinga

MyMD Pharmaceuticals Announces New Data on Its Lead Compound MYMD-1 from a Phenotypic Study Performed by Eurofins Dis...

BALTIMORE--(BUSINESS WIRE)--Akers Biosciences, Inc. (Nasdaq: AKER), with its proposed merger partner MyMD Pharmaceuticals, Inc. (“MyMD”), a clinical stage pharmaceutical company committed to extending h...

8 months ago - Business Wire

Study Identifies Effects of Temperature Changes on SARS-CoV-2 Transmission

BALTIMORE--(BUSINESS WIRE)--Akers Biosciences, Inc. (Nasdaq: AKER), with its proposed merger partner MyMD Pharmaceuticals, Inc. (“MyMD”), a clinical stage pharmaceutical company committed to extending h...

8 months ago - Business Wire